Your browser is no longer supported. Please, upgrade your browser.
TRACON Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.59 Insider Own1.20% Shs Outstand15.50M Perf Week-6.10%
Market Cap69.17M Forward P/E- EPS next Y-1.34 Insider Trans7.86% Shs Float13.94M Perf Month-17.10%
Income-22.30M PEG- EPS next Q-0.32 Inst Own47.70% Short Float2.22% Perf Quarter-6.35%
Sales0.30M P/S230.57 EPS this Y75.00% Inst Trans-2.83% Short Ratio1.54 Perf Half Y-54.03%
Book/sh0.77 P/B4.60 EPS next Y11.10% ROA-72.00% Target Price11.86 Perf Year-28.34%
Cash/sh1.31 P/C2.70 EPS next 5Y- ROE-122.50% 52W Range3.21 - 12.20 Perf YTD-69.74%
Dividend- P/FCF- EPS past 5Y38.90% ROI- 52W High-71.07% Beta1.74
Dividend %- Quick Ratio1.80 Sales past 5Y- Gross Margin- 52W Low9.94% ATR0.25
Employees18 Current Ratio1.80 Sales Q/Q- Oper. Margin- RSI (14)38.81 Volatility7.36% 6.89%
OptionableYes Debt/Eq0.24 EPS Q/Q17.20% Profit Margin- Rel Volume0.51 Prev Close3.54
ShortableYes LT Debt/Eq0.00 EarningsAug 11 AMC Payout- Avg Volume201.13K Price3.53
Recom1.90 SMA20-7.41% SMA50-7.77% SMA200-46.02% Volume10,120 Change-0.31%
Apr-16-21Upgrade BTIG Research Neutral → Buy $14
Feb-10-21Initiated Maxim Group Buy $24
Dec-23-19Reiterated H.C. Wainwright Buy $15 → $18
Mar-01-19Reiterated Needham Buy $7
Jun-13-17Reiterated Stifel Buy $14 → $6
Dec-21-16Initiated Jefferies Buy $10
Feb-01-16Resumed Oppenheimer Outperform
Jul-29-15Initiated ROTH Capital Buy $18
Mar-02-15Reiterated Stifel Buy $16 → $20
Mar-02-15Reiterated Oppenheimer Outperform $22 → $26
Feb-24-15Initiated Stifel Buy $16
Feb-24-15Initiated Oppenheimer Outperform $22
Oct-13-21 08:00AM  
Oct-11-21 01:27PM  
Sep-13-21 08:05AM  
Sep-07-21 08:05AM  
Sep-02-21 08:05AM  
Aug-11-21 04:02PM  
Aug-09-21 08:05AM  
Aug-03-21 08:05AM  
Jul-28-21 08:05AM  
Jul-21-21 10:30PM  
Jul-20-21 08:05AM  
Jun-30-21 08:05AM  
Jun-29-21 08:05AM  
Jun-28-21 01:04PM  
Jun-18-21 10:08AM  
Jun-04-21 09:01AM  
Jun-01-21 08:05AM  
May-25-21 08:05AM  
May-20-21 08:05AM  
May-05-21 04:03PM  
May-03-21 08:05AM  
Apr-28-21 08:05AM  
Apr-26-21 08:00AM  
Mar-23-21 08:05AM  
Mar-09-21 08:05AM  
Mar-08-21 08:05AM  
Mar-02-21 08:05AM  
Feb-25-21 04:03PM  
Feb-18-21 08:05AM  
Jan-28-21 11:40AM  
Jan-19-21 08:05AM  
Jan-06-21 08:05AM  
Dec-30-20 08:05AM  
Dec-29-20 08:05AM  
Dec-22-20 08:05AM  
Dec-10-20 08:05AM  
Dec-04-20 08:29AM  
Dec-03-20 09:14AM  
Nov-30-20 04:17PM  
Nov-23-20 08:05AM  
Nov-16-20 09:45AM  
Nov-10-20 04:03PM  
Nov-03-20 08:05AM  
Oct-26-20 08:05AM  
Sep-25-20 11:29AM  
Sep-21-20 08:05AM  
Sep-10-20 08:05AM  
Sep-09-20 11:51AM  
Sep-03-20 08:05AM  
Aug-31-20 08:05AM  
Aug-27-20 08:05AM  
Aug-25-20 11:49AM  
Aug-24-20 11:59AM  
Aug-17-20 11:08AM  
Aug-05-20 04:05PM  
Aug-03-20 08:05AM  
Jul-29-20 04:05PM  
Jul-16-20 08:15AM  
Jul-13-20 08:15AM  
Jun-22-20 02:19PM  
Jun-11-20 10:56PM  
Jun-05-20 02:48PM  
Jun-01-20 08:05AM  
May-29-20 08:20AM  
May-14-20 08:32AM  
May-13-20 04:04PM  
May-11-20 08:15AM  
May-06-20 04:05PM  
Apr-24-20 08:15AM  
Apr-14-20 08:15AM  
Apr-06-20 08:15AM  
Mar-19-20 08:15AM  
Mar-18-20 03:29AM  
Mar-16-20 08:15AM  
Mar-09-20 07:40PM  
Feb-28-20 07:28AM  
Feb-27-20 04:03PM  
Feb-20-20 06:00PM  
Feb-07-20 08:05AM  
Jan-20-20 01:14PM  
Dec-22-19 05:10PM  
Dec-20-19 08:58AM  
Nov-21-19 09:37PM  
Nov-08-19 08:05AM  
Nov-05-19 04:05PM  
Oct-29-19 04:15PM  
Oct-21-19 08:05AM  
Oct-07-19 12:40PM  
Sep-03-19 08:05AM  
Aug-29-19 08:05AM  
TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and age-related macular degeneration and fibrotic diseases in the United States. Its lead clinical stage product include envafolimab (KN035), an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma. The company's clinical stage products also include TRC102, which is a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, Phase I clinical trial to treat solid tumors, Phase I to treat solid tumors and lymphomas, and Phase I trial to treat lung cancer; TRC253, a small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Janssen Pharmaceutica N.V. for the development of TRC253; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
THEUER CHARLESPresident and CEOAug 16Buy3.563,00010,680207,732Aug 18 06:05 AM
Brown Scott B.Chief Financial OfficerAug 13Buy3.691,0003,6957,628Aug 17 05:01 PM
PELLETIER SAUNDRA LDirectorJul 26Buy3.826,54525,00212,045Jul 27 06:00 AM
LARUE WILLIAM RDirectorJul 26Buy3.826,54525,0027,883Jul 27 06:00 AM
Brown Scott B.Chief Financial OfficerMar 08Buy8.301,0008,2963,128Mar 09 06:00 AM
THEUER CHARLESPresident and CEOJan 27Buy8.9811,00098,771201,232Jan 28 06:00 AM
Ikarian Capital, LLCMember of 10% GroupDec 30Buy9.61520,2914,999,9972,716,840Dec 30 06:24 PM
THEUER CHARLESPresident and CEODec 29Buy9.981,0009,980190,232Dec 30 06:00 AM
WIGGINS MARK CChief Business OfficerDec 29Buy10.571,00010,57013,700Dec 30 06:00 AM
Opaleye Management Inc.10% OwnerDec 22Buy8.06496,2773,999,9932,293,371Dec 28 09:53 AM
Ikarian Capital, LLCMember of 10% GroupNov 11Buy7.535,00037,6292,196,549Nov 12 06:18 PM
Ikarian Capital, LLCMember of 10% GroupOct 30Buy4.6421,30098,9072,191,549Nov 12 06:18 PM
Ikarian Capital, LLCMember of 10% GroupOct 29Buy4.777,70036,7342,170,249Nov 12 06:18 PM